Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status: Enrolling
Updated:  12/13/2016
The University of California, San Diego
mi
from
La Jolla, CA
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status: Enrolling
Updated: 12/13/2016
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status: Enrolling
Updated:  12/13/2016
Coordinated Clinical Research
mi
from
San Diego, CA
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status: Enrolling
Updated: 12/13/2016
Coordinated Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status: Enrolling
Updated:  12/13/2016
George Washington University
mi
from
Washington,
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status: Enrolling
Updated: 12/13/2016
George Washington University
mi
from
Washington,
Click here to add this to my saved trials
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status: Enrolling
Updated:  12/13/2016
SUNY Upstate Medical University
mi
from
Syracuse, NY
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status: Enrolling
Updated: 12/13/2016
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status: Enrolling
Updated:  12/13/2016
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status: Enrolling
Updated: 12/13/2016
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status: Enrolling
Updated:  12/13/2016
Providence ALS Center
mi
from
Portand, OR
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status: Enrolling
Updated: 12/13/2016
Providence ALS Center
mi
from
Portand, OR
Click here to add this to my saved trials
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status: Enrolling
Updated:  12/13/2016
Texas Neurology, PA
mi
from
Dallas, TX
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status: Enrolling
Updated: 12/13/2016
Texas Neurology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status: Enrolling
Updated:  12/13/2016
Heritage Medical Research
mi
from
Calgary,
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status: Enrolling
Updated: 12/13/2016
Heritage Medical Research
mi
from
Calgary,
Click here to add this to my saved trials
Neural Prostheses and Gait Performance: Model-Based Strategies
Neural Prostheses and Gait Performance: Model-Based Strategies
Status: Enrolling
Updated:  12/14/2016
Louis Stokes VA Medical Center, Cleveland, OH
mi
from
Cleveland, OH
Neural Prostheses and Gait Performance: Model-Based Strategies
Neural Prostheses and Gait Performance: Model-Based Strategies
Status: Enrolling
Updated: 12/14/2016
Louis Stokes VA Medical Center, Cleveland, OH
mi
from
Cleveland, OH
Click here to add this to my saved trials
Comparing School Based Interventions for Adolescents With Attention Deficit Hyperactivity Disorder
Multisite Study of School Based Treatment Approaches for ADHD Adolescents
Status: Enrolling
Updated:  12/15/2016
Ohio University
mi
from
Athens, OH
Comparing School Based Interventions for Adolescents With Attention Deficit Hyperactivity Disorder
Multisite Study of School Based Treatment Approaches for ADHD Adolescents
Status: Enrolling
Updated: 12/15/2016
Ohio University
mi
from
Athens, OH
Click here to add this to my saved trials
Comparing School Based Interventions for Adolescents With Attention Deficit Hyperactivity Disorder
Multisite Study of School Based Treatment Approaches for ADHD Adolescents
Status: Enrolling
Updated:  12/15/2016
Cincinnati Children's Hospital Medical Center, Center for ADHD
mi
from
Cincinnati, OH
Comparing School Based Interventions for Adolescents With Attention Deficit Hyperactivity Disorder
Multisite Study of School Based Treatment Approaches for ADHD Adolescents
Status: Enrolling
Updated: 12/15/2016
Cincinnati Children's Hospital Medical Center, Center for ADHD
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects
Status: Enrolling
Updated:  12/15/2016
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects
Status: Enrolling
Updated: 12/15/2016
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Click here to add this to my saved trials
Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension
Endothelial Mircroparticles as a Biomarker of Pulmonary Hypertension in Systemic Sclerosis
Status: Enrolling
Updated:  12/15/2016
Lsu Health Sciences Center
mi
from
New Orleans, LA
Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension
Endothelial Mircroparticles as a Biomarker of Pulmonary Hypertension in Systemic Sclerosis
Status: Enrolling
Updated: 12/15/2016
Lsu Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies
Status: Enrolling
Updated:  12/15/2016
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies
Status: Enrolling
Updated: 12/15/2016
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Click here to add this to my saved trials
An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome
Ketamine for the Treatment of Rett Syndrome: An Exploratory Trial
Status: Enrolling
Updated:  12/15/2016
Cleveland Clinic
mi
from
Cleveland, OH
An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome
Ketamine for the Treatment of Rett Syndrome: An Exploratory Trial
Status: Enrolling
Updated: 12/15/2016
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
Status: Enrolling
Updated:  12/19/2016
Queen's Medical Center
mi
from
Honolulu, HI
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
Status: Enrolling
Updated: 12/19/2016
Queen's Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
Status: Enrolling
Updated:  12/19/2016
Johns Hopkins University
mi
from
Baltimore, MD
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
Status: Enrolling
Updated: 12/19/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
Status: Enrolling
Updated:  12/19/2016
New York Presbyterian Hospital-Weill Cornell Medical Center
mi
from
New York, NY
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
Status: Enrolling
Updated: 12/19/2016
New York Presbyterian Hospital-Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
Status: Enrolling
Updated:  12/19/2016
Oregon Health and Science University
mi
from
Portland, OR
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
Status: Enrolling
Updated: 12/19/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
Status: Enrolling
Updated:  12/19/2016
University of Pennsylvania School of Medicine
mi
from
Philadelphia, PA
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
Status: Enrolling
Updated: 12/19/2016
University of Pennsylvania School of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
Status: Enrolling
Updated:  12/19/2016
University of Texas Medical School in Houston
mi
from
Houston, TX
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
Status: Enrolling
Updated: 12/19/2016
University of Texas Medical School in Houston
mi
from
Houston, TX
Click here to add this to my saved trials
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
Status: Enrolling
Updated:  12/19/2016
Baylor College of Medicine
mi
from
Houston, TX
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
Status: Enrolling
Updated: 12/19/2016
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
An Open-Label, Single-Sequence Study to Evaluate the Effect of Diltiazem on the Single-Dose Pharmacokinetics of BMS-986141 in Healthy Subjects
Status: Enrolling
Updated:  12/19/2016
PPD Development
mi
from
Austin, TX
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
An Open-Label, Single-Sequence Study to Evaluate the Effect of Diltiazem on the Single-Dose Pharmacokinetics of BMS-986141 in Healthy Subjects
Status: Enrolling
Updated: 12/19/2016
PPD Development
mi
from
Austin, TX
Click here to add this to my saved trials
Omega-3 Supplementation to ADHD Medication in Children
A Pilot Study of Omega-3 Fatty Acid Supplementation to ADHD Medication in Children With ADHD and Deficits in Emotional Self-Regulation
Status: Enrolling
Updated:  12/20/2016
Massachusetts General Hospital
mi
from
Boston, MA
Omega-3 Supplementation to ADHD Medication in Children
A Pilot Study of Omega-3 Fatty Acid Supplementation to ADHD Medication in Children With ADHD and Deficits in Emotional Self-Regulation
Status: Enrolling
Updated: 12/20/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
Cullman, AL
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
Cullman, AL
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
Fort Collins, CO
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
Washington,
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
Ormond Beach, FL
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
Tampa, FL
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
Latham, NY
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
Latham, NY
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
Knoxville, TN
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
Round Rock, TX
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
Round Rock, TX
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
San Antonio, TX
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
Seattle, WA
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/20/2016
Investigational Site Number 124001
mi
from
Greenfield Park,
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/20/2016
Investigational Site Number 124001
mi
from
Greenfield Park,
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
Cullman, AL
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
Cullman, AL
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
Fort Collins, CO
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
Ormond Beach, FL
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
Latham, NY
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
Latham, NY
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
Round Rock, TX
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
Round Rock, TX
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
Status: Enrolling
Updated:  12/20/2016
Clinical Research Facility
mi
from
San Antonio, TX
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
Status: Enrolling
Updated: 12/20/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
Status: Enrolling
Updated:  12/20/2016
Investigational Site Number 124001
mi
from
Greenfield Park,
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
Status: Enrolling
Updated: 12/20/2016
Investigational Site Number 124001
mi
from
Greenfield Park,
Click here to add this to my saved trials
A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain
A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain
Status: Enrolling
Updated:  12/21/2016
Columbia University Medical Center
mi
from
New York, NY
A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain
A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain
Status: Enrolling
Updated: 12/21/2016
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)
Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS)In Participants With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/22/2016
Barrow Neurological Institute
mi
from
Phoenix, AZ
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)
Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS)In Participants With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/22/2016
Barrow Neurological Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)
Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS)In Participants With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/22/2016
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)
Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS)In Participants With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/22/2016
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)
Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS)In Participants With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/22/2016
California Pacific Medical Center
mi
from
San Diego, CA
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)
Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS)In Participants With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/22/2016
California Pacific Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)
Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS)In Participants With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/22/2016
Stanford University
mi
from
Stanford, CA
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)
Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS)In Participants With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/22/2016
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)
Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS)In Participants With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/22/2016
Hospital for Special Care
mi
from
New Britain, CT
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)
Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS)In Participants With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/22/2016
Hospital for Special Care
mi
from
New Britain, CT
Click here to add this to my saved trials